Home » Topics » BioWorld Science

BioWorld Science
RSS

Pediatric registrational trial of rivogenlecleucel meets primary endpoint

July 9, 2019

Promising topline results presented from phase III program of Epsolay in papulopustular rosacea

July 9, 2019

Enanta initiates phase I study of EDP-514 for the treatment of HBV infection

July 9, 2019

Emmaus Life Sciences screens first patient in phase I diverticulosis study

July 9, 2019

PTEN and CF

July 9, 2019

Botox for -- well, against -- mosquitoes

July 9, 2019

Novel rat model of multiple system atrophy unresponsive to L-dopa

July 9, 2019

DMC recommends continuation of phase Ib study of AVB-500 in ovarian cancer

July 8, 2019

Intra-Cellular Therapies reports topline phase III data on lumateperone in bipolar depression

July 8, 2019

FDA accepts Celyad's IND application for autologous NKG2D-based CAR-T cell therapy CYAD-02

July 8, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 4, 2026.
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.
EQ-504 is AhR agonist for ulcerative colitis, related disorders
BioWorld Science
Activating the aryl hydrocarbon receptor (AhR) in immune cells enhances anti-inflammatory pathways and limits pathogenic immune responses. Equillium Inc. has...
Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control
BioWorld
A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...